← Leaderboards
Richard K. Plemper
Georgia State University
$28,083,812
Attributed
$30,336,062
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $58.2M · FY2005–25$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$82,250,942 · 15
By mechanism
U19$56,054,210 · 2
R01$24,343,903 · 7
R21$1,276,701 · 3
R56$379,906 · 1
U54$171,222 · 1
R03$25,000 · 1
Top collaborators
- Matthias Johannes Schnell3 shared
- George Robert Painter2 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsViralAntiviral AgentsVirusVirus DiseasesPharmaceutical PreparationsPathogenVaccinesPilot ProjectsResistanceLeadInfectionInnovationDesignProgramsBaseFamilyAnalogIn VivoReporterParamyxovirusMemberHigh Throughput ScreeningScaffold
Grant awards (52)
Developing Inhibitors of Seasonal and Pandemic Influenza Viruses$3,323,410
R01 · FY2025 · AI · contact PI
Polymerase Inhibitors of Respiratory Syncytial Virus$689,381
R01 · FY2024 · AI · contact PI
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses$913,220
R01 · FY2023 · AI · contact PI
Polymerase Inhibitors of Respiratory Syncytial Virus$689,381
R01 · FY2023 · AI · contact PI
Antiviral Countermeasures Development Center (AC/DC)$51,914,880
U19 · FY2022 · AI
Project 1 â Development of Orally Bioavailable beta-CoV Inhibitors$4,139,330
U19 · FY2022 · AI · contact PI
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses$960,276
R01 · FY2022 · AI · contact PI
Polymerase Inhibitors of Respiratory Syncytial Virus$689,381
R01 · FY2022 · AI · contact PI
Developing Combination Therapies against Pneumo- and Paramyxoviruses Causing Severe Respiratory Infection$539,337
R01 · FY2022 · AI · contact PI
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses$979,627
R01 · FY2021 · AI · contact PI
Polymerase Inhibitors of Respiratory Syncytial Virus$780,845
R01 · FY2021 · AI · contact PI
Developing Combination Therapies against Pneumo- and Paramyxoviruses Causing Severe Respiratory Infection$539,799
R01 · FY2021 · AI · contact PI
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses$1,041,945
R01 · FY2020 · AI · contact PI
Polymerase Inhibitors of Respiratory Syncytial Virus$806,958
R01 · FY2020 · AI · contact PI
Developing Combination Therapies against Pneumo- and Paramyxoviruses Causing Severe Respiratory Infection$539,402
R01 · FY2020 · AI · contact PI
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses$1,103,435
R01 · FY2019 · AI · contact PI
Developing Combination Therapies against Pneumo- and Paramyxoviruses Causing Severe Respiratory Infection$542,783
R01 · FY2019 · AI · contact PI
Drug discovery against lyssaviruses by high thoughput screening$398,340
R01 · FY2019 · AI
Developing Combination Therapies against Pneumo- and Paramyxoviruses Causing Severe Respiratory Infection$587,657
R01 · FY2018 · AI · contact PI
Novel Therapeutics against Respiratory Syncytial Virus Infection$542,589
R01 · FY2018 · HD · contact PI
Drug discovery against lyssaviruses by high thoughput screening$384,375
R01 · FY2018 · AI
Novel Therapeutics against Respiratory Syncytial Virus Infection$552,559
R01 · FY2017 · HD · contact PI
Drug discovery against lyssaviruses by high thoughput screening$398,375
R01 · FY2017 · AI
Novel Therapeutics against Respiratory Syncytial Virus Infection$556,677
R01 · FY2016 · HD · contact PI
Developing Myxovirus Inhibitors with Expanded Pathogen Target Range$364,182
R01 · FY2016 · AI · contact PI
Identification and Hit-to-Lead Development of Influenza A Virus Inhibitors$199,226
R21 · FY2016 · AI · contact PI
Novel Therapeutics against Respiratory Syncytial Virus Infection$534,826
R01 · FY2015 · HD · contact PI
Developing Myxovirus Inhibitors with Expanded Pathogen Target Range$364,182
R01 · FY2015 · AI · contact PI
Cryo-Electron and Biochemical Anaysis of Native Paramyxovirus Fusion Complexes$339,554
R01 · FY2015 · AI · contact PI
Identification and Hit-to-Lead Development of Influenza A Virus Inhibitors$236,906
R21 · FY2015 · AI · contact PI
Novel Therapeutics against Respiratory Syncytial Virus Infection$622,945
R01 · FY2014 · HD · contact PI
Developing Myxovirus Inhibitors with Expanded Pathogen Target Range$364,182
R01 · FY2014 · AI · contact PI
Cryo-Electron and Biochemical Anaysis of Native Paramyxovirus Fusion Complexes$339,554
R01 · FY2014 · AI · contact PI
Developing Myxovirus Inhibitors with Expanded Pathogen Target Range$345,739
R01 · FY2013 · AI · contact PI
Cryo-Electron and Biochemical Anaysis of Native Paramyxovirus Fusion Complexes$330,460
R01 · FY2013 · AI · contact PI
Developing Myxovirus Inhibitors with Expanded Pathogen Target Range$307,824
R01 · FY2012 · AI · contact PI
Cryo-Electron and Biochemical Analysis of Native Paramyxovirus Fusion Complexes$240,434
R01 · FY2012 · AI · contact PI
Host-Directed Inhibitors of Myxovirus Replication$171,222
U54 · FY2012 · AI · contact PI
Cryo-Electron and Biochemical Anaysis of Native Paramyxovirus Fusion Complexes$145,004
R01 · FY2012 · AI · contact PI
Developing Myxovirus Inhibitors with Expanded Pathogen Target Range$143,371
R01 · FY2012 · AI · contact PI
Cryo-Electron and Biochemical Analysis of Native Paramyxovirus Fusion Complexes$353,146
R01 · FY2011 · AI · contact PI
Counteracting Resistance through Host-Directed Myxovirus Inhibitors$191,813
R21 · FY2011 · AI · contact PI
Cryo-Electron and Biochemical Analysis of Native Paramyxovirus Fusion Complexes$379,906
R56 · FY2010 · AI · contact PI
Identification and Pre-Clinical Evaluation of Measles Virus Inhibitors$360,179
R01 · FY2010 · AI · contact PI
Counteracting Resistance through Host-Directed Myxovirus Inhibitors$232,500
R21 · FY2010 · AI · contact PI
Identification and Pre-Clinical Evaluation of Measles Virus Inhibitors$498,715
R01 · FY2009 · AI · contact PI
Identification and Pre-Clinical Evaluation of Measles Virus Inhibitors$363,817
R01 · FY2008 · AI · contact PI
Identification and Pre-Clinical Evaluation of Measles Virus Inhibitors$371,419
R01 · FY2007 · AI · contact PI
High Throughput Screening-Based Identification of Measles Virus Probes$25,000
R03 · FY2007 · MH · contact PI
Identification and Pre-Clinical Evaluation of Measles Virus Inhibitors$394,618
R01 · FY2006 · AI · contact PI
Structure-Based Design of Nipah Virus Entry Inhibitors$186,756
R21 · FY2006 · AI · contact PI
Structure-Based Design of Nipah Virus Entry Inhibitors$229,500
R21 · FY2005 · AI